REPLIGEN CORP Stock Issued During Period, Value, New Issues
New shares the company issued (share-based compensation, option exercises, employee stock purchase plans, new issues, acquisitions), as filed in its 10-Q and 10-K XBRL statement of shareholders' equity. This is the dilution side; Issuer Repurchases is the other side.
- REPLIGEN CORP stock issued during period, value, new issues for the quarter ending 2019-12-31 was $0.00.
- REPLIGEN CORP stock issued during period, value, new issues for the quarter ending 2019-09-30 was $131.09M.
- REPLIGEN CORP stock issued during period, value, new issues for the quarter ending 2019-06-30 was $189.62M.
- REPLIGEN CORP stock issued during period, value, new issues for fiscal 2020 was $297.77M, a 7.15% decline from fiscal 2019.
- REPLIGEN CORP stock issued during period, value, new issues for fiscal 2019 was $320.71M.
- REPLIGEN CORP stock issued during period, value, new issues for fiscal 2017 was $129.31M.
| Period end | Stock Issued During Period, Value, New Issues 3 month | Stock Issued During Period, Value, New Issues 12 month |
|---|---|---|
| 2020-12-31 | $297.77M 10-K · filed 2023-02-22 | |
| 2019-12-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2022-02-17 | $320.71M 10-K · filed 2022-02-17 |
| 2019-09-30 | $131.09M 10-Q · filed 2020-11-05 | |
| 2019-06-30 | $189.62M 10-Q · filed 2020-07-30 | |
| 2017-12-31 | $129.31M 10-K · filed 2020-02-26 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Krystal Biotech, Inc. (KRYS) | United States | $10.210B | 45.56 |
| BIO-TECHNE Corp (TECH) | United States | $11.379B | 74.68 |
| Twist Bioscience Corp (TWST) | United States | $11.540B | -47.21 |
| Kymera Therapeutics, Inc. (KYMR) | United States | $9.631B | -31.69 |
| ImmunityBio, Inc. (IBRX) | United States | $9.157B | -9.29 |
| Vaxcyte, Inc. (PCVX) | United States | $8.466B | -7.91 |
| HALOZYME THERAPEUTICS, INC. (HALO) | United States | $13.083B | 21.59 |
| NEUROCRINE BIOSCIENCES INC (NBIX) | United States | $14.131B | 24.25 |
| EXELIXIS, INC. (EXEL) | United States | $14.358B | 16.15 |
| Immunovant, Inc. (IMVT) | United States | $7.028B | -14.78 |